news

Study finds B cells could improve immunotherapies for cancer

Researchers have discovered that B cells aid T cells in fighting cancer, which could be an area of development for immunotherapies.

image representing immunotherapies

A study has identified a potential pathway for improving therapies to combat cancer. The researchers found that B cells could enhance immunotherapy to treat melanoma, which is currently focused on T cells.

The investigation was conducted by the European Molecular Biology Laboratory’s (EMBL) European Bioinformatics Institute, UK and the Medical University of Vienna, Austria.

Established immunotherapies utilise T cells, which form an essential arm of the immune system’s fight against cancer cells. However, the researchers found that B cells can guide T cells to tumours via the secretion of distinct messenger molecules.

 

Reserve your FREE place

 


Are you advancing promising antibody leads, only to encounter issues with stability, PK or manufacturability later in development?

30 July 2025 | 10:00 AM BST | FREE Webinar

Join us for an expert-led webinar exploring how early-stage developability assessment can help reduce downstream risk and improve candidate selection.

What You’ll Learn:

  • How to identify key developability risks early including aggregation, PK, and manufacturability
  • How to implement high-throughput in vitro assays requiring <1 mg of antibody per test
  • How to combine in silico modeling with wet-lab analytics to guide early optimisation

Don’t miss your chance to learn from Dr Lei Guo.

Register Now – It’s Free!

 

The team observed that when B cells were depleted from melanoma patients, the number of T cells and other immune cells dramatically decreased within tumours. In subsequent experiments, the researchers showed that a certain subtype of B cells appeared to be responsible for guiding T cells and other immune cells to tumours.

Using multiplex-immunostaining to characterise B cells (credit: Christine Wagner).

The melanoma cells seemed to force the B cells to develop into their subtype. The team found that the specific subtype also increased activation of current immune therapies on T cells and promoted higher numbers of this B cell subtype in tumours.

“For the first time, we found that B cells also play an important part in the process and help T cells find the tumour. The role of B cells in immunotherapy is still largely unknown, but it seems they may have more impact than previously thought,” explains Johannes Griss, Researcher at the Medical University of Vienna and EMBL-EBI.

According to the researchers, more investigation is needed into the mechanisms driving B cells, but this could support current immunotherapies in cancer patients.

The results were published in Nature Communications.

Leave a Reply

Your email address will not be published. Required fields are marked *